The evaluation criteria and implementation rules for NMPA certified medical devices in China are governed by specific regulations and guidelines set forth by the National Medical Products Administration (NMPA). Here’s an overview of the key aspects:
Evaluation Criteria:
Safety: The primary consideration is the safety of the medical device for its intended use. This includes assessing potential risks associated with the device and ensuring adequate measures are in place to mitigate these risks.
Effectiveness: The device must demonstrate effectiveness in achieving its intended purpose. This involves performance testing to verify that the device functions as specified and meets applicable performance standards.
Quality: Quality criteria focus on the manufacturing processes, materials used, and adherence to quality management standards such as ISO 13485. Documentation of a comprehensive quality management system (QMS) is essential.
Clinical Evaluation: For higher-risk devices, clinical data is required to demonstrate safety and efficacy. This may involve clinical trials conducted in China or data from equivalent studies that meet NMPA’s standards.
Biocompatibility: Devices must undergo biocompatibility testing according to ISO 10993 standards to ensure that materials used in the device are compatible with the human body and do not cause adverse reactions.
Electromagnetic Compatibility (EMC): Compliance with EMC requirements ensures that the device does not interfere with other electronic equipment and operates safely in its intended environment.
Labeling and Instructions for Use: The device labeling must be clear, accurate, and include instructions for use in Chinese. It should provide sufficient information for safe and effective use of the device by healthcare professionals and patients.
Implementation Rules:
Regulatory Pathways: Different regulatory pathways exist based on the classification and risk level of the medical device. These pathways determine the specific requirements and documentation needed for NMPA certification.
Documentation Requirements: Detailed technical documentation must be prepared and submitted to NMPA, including device description, design drawings, test reports, clinical data, and quality management documentation.
Inspection and Audits: Depending on the risk classification, NMPA may conduct on-site inspections of manufacturing facilities and audits of the quality management system to ensure compliance with regulations.
Post-Market Surveillance: Manufacturers are required to implement post-market surveillance systems to monitor the performance of devices once they are on the market. This includes reporting adverse events and taking corrective actions as necessary.
Authorized Representative (AR): Foreign manufacturers must appoint an Authorized Representative (AR) in China who takes responsibility for regulatory compliance and acts as a liaison with NMPA.
Timelines and Review Process: The review process for NMPA certification involves a technical review of submitted documentation, which may include a review committee for high-risk devices. Timelines for approval vary based on the complexity and completeness of the submission.
Understanding and complying with these evaluation criteria and implementation rules are crucial for successful NMPA certification of medical devices in China. Engaging with regulatory experts or consultants familiar with NMPA regulations can help navigate these requirements effectively.
Contact Us：
Whatsapp or Wechat：+86 15816864648；email address：hito.lin@grzan.cn
.png)
.jpg "1 - 副本(2).jpg")
